All In Biotech

Drug Trial Radar · NCT01387737

Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus

An Open-Label, Multicenter Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of TA-7284 in Subjects With Type 2 Diabetes Mellitus

Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,299 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,299

Actual

Start

May 2011

Primary completion

Nov 2012

Study completion Dec 2012

Sponsor

Lead sponsor
Tanabe Pharma CorporationIndustry
Sponsor type
Industry
First posted
Jul 6, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of TA-7284 as monotherapy or combination therapy with other oral anti-hyperglycaemic agent in Japanese patients with Type 2 diabetes mellitus on 52 weeks oral administration.

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • TA-7284-LowDrug

    TA-7284-Low

  • TA-7284-HighDrug

    TA-7284-High

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability Assessed by Adverse Events, Hypoglycemic EventsTime frame: 54 weeks

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Research site

    Chugoku, Japan

  • Research site

    Hokkaido, Japan

  • Research site

    Kanto, Japan

  • Research site

    Kinki, Japan

  • Research site

    Kyushu, Japan

  • Research site

    Shikoku, Japan

  • Research site

    Tōhoku, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.